Hot Flashes Treatment Pipeline Analysis 2025

DelveInsight's "Hot Flashes Pipeline Analysis 2025" delivers extensive intelligence on over 15 pharmaceutical firms and more than 15 investigational medications within the Hot Flashes development arena. The analysis encompasses profiles of Hot Flashes therapeutic candidates, spanning both clinical and preclinical phases. Additionally, it includes evaluation of Hot Flashes investigational treatments by product category, developmental phase, administration method, and molecular classification. The report also spotlights dormant development programs in this therapeutic area.

Interested in recent developments within the Hot Flashes Pipeline? Discover the emerging treatments and clinical studies generating attention @ Hot Flashes Pipeline Outlook Report

Primary Highlights from the Hot Flashes Pipeline Analysis

On October 29, 2025, Bayer initiated research to examine the effectiveness of elinzanetant in managing hot flashes triggered by anticancer treatments in women diagnosed with or at elevated risk for HR-positive breast cancer, using placebo as a comparator. A placebo represents a treatment that resembles medication but contains no active therapeutic ingredients.

On October 28, 2025, Astellas Pharma Inc. revealed that a clinical study will validate whether fezolintant effectively decreases the frequency of hot flashes in Japanese menopausal women. Participants interested in the research will receive an electronic portable device equipped with an application to monitor their hot flashes. Selected participants may have the option to utilize the application on their personal smartphones. Prior to treatment allocation, participants will document details regarding their hot flashes.

DelveInsight's Hot Flashes Pipeline analysis reveals a dynamic field featuring more than 15 engaged entities advancing over 15 investigational treatments for Hot Flashes management.

Major Hot Flashes pharmaceutical firms include Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, Pherin Pharmaceuticals, and additional organizations.

Notable Hot Flashes investigational medications include Fezolinetant, NK3R antagonist-AZD4901, Tamoxifen, FP-101, MF101, Gabapentin, RAD1901, among others.

Curious about which pharmaceutical companies are pioneering advancement in Hot Flashes treatment? Explore comprehensive pipeline intelligence @ Hot Flashes Clinical Trials Assessment

The Hot Flashes Pipeline Analysis delivers a condition synopsis, pipeline landscape, and therapeutic evaluation of principal investigational therapies within this domain. The analysis also emphasizes unaddressed medical requirements concerning Hot Flashes.

Hot Flashes Background

Hot flashes (HFs) represent a rapid and amplified heat release mechanism, characterized by abundant perspiration, peripheral blood vessel dilation, and sensations of extreme, internal warmth. They occur due to minor increases in core body temperature (Tc) operating within a significantly narrowed thermoneutral zone—specifically, the Tc range between the upper threshold (perspiration) and lower threshold (shivering).

Hot Flashes Investigational Drug Profiles

Fezolinetant: Astellas Pharma

Fezolinetant is an experimental selective neurokinin-3 (NK3) receptor antagonist. The safety profile and therapeutic efficacy of fezolinetant remain under evaluation and are not yet confirmed. Upon potential approval by regulatory agencies, fezolinetant would represent a pioneering, non-hormonal therapeutic alternative for reducing the frequency and intensity of VMS related to menopause.

Elinzanetant: Bayer

Elinzanetant is a pioneering, non-hormonal, orally delivered, dual neurokinin-1,3 receptor antagonist presently undergoing clinical evaluation for managing vasomotor symptoms throughout menopause. Elinzanetant targets vasomotor symptoms through modulation of estrogen-responsive neurons within the hypothalamus (the KNDy neurons), which, due to estrogen deficiency, exhibit hyperactivity in menopausal women and subsequently interfere with thermoregulatory mechanisms, producing the distressing vasomotor manifestations of hot flashes.

Fezolinetant: Ogeda

Fezolinetant (ESN364) is a proprietary, orally administered, small-molecule compound, identified and created by Ogeda for managing women's health conditions. Fezolinetant's therapeutic mechanism to replicate the neuronal impacts of estrogen for temperature regulation enables fezolinetant to directly and safely target the underlying cause of hot flashes in menopausal women. Furthermore, fezolinetant addresses the etiology of PCOS by selectively reducing luteinizing hormone (LH) while maintaining follicle-stimulating hormone (FSH) levels to restore the appropriate LH-to-FSH balance and enable resumption of menstrual cycle regularity and reproductive capacity. Fezolinetant also surpasses current, commercialized gonadotropin-releasing hormone (GnRH) ligands by decreasing ovarian hormone levels of estrogen and progesterone in a non-castrating fashion as needed for safe, effective management of uterine fibroids and endometriosis.

Zuclomiphene citrate: Veru Inc

Zuclomiphene citrate is a novel, proprietary, orally administered, nonsteroidal, estrogen receptor agonist. Recently, the organization disclosed that a Phase 2 clinical investigation of Zuclomiphene citrate achieved a statistically significant decrease in the occurrence of moderate to severe hot flashes in males with advanced prostate cancer receiving ADT therapy.

Monitoring active Hot Flashes Clinical investigations? This announcement is essential reading. Access the latest advances @ Hot Flashes Treatment Drugs

The Hot Flashes Pipeline Analysis Offers Intelligence On:

The analysis delivers detailed intelligence regarding pharmaceutical companies developing therapeutics for Hot Flashes management, including cumulative therapies created by each organization for this indication.

It evaluates various therapeutic candidates categorized into early-phase, mid-phase, and late-phase development for Hot Flashes Treatment.

Hot Flashes pharmaceutical firms engaged in targeted therapeutic development with corresponding active and inactive (dormant or terminated) initiatives.

Hot Flashes investigational medications classified by developmental phase, administration method, target receptor, monotherapy or combination therapy, distinct mechanism of action, and molecular classification.

Comprehensive analysis of partnerships (company-to-company collaborations and company-to-academia partnerships), licensing arrangements, and funding particulars for future progression of the Hot Flashes market.

Hot Flashes Pharmaceutical Firms

Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, Pherin Pharmaceuticals, and additional organizations.

The Hot Flashes pipeline analysis presents therapeutic evaluation of investigational medications by Administration Method. Products are classified under multiple administration routes including:

• Oral

• Intravenous

• Subcutaneous

Hot Flashes products are classified under various molecular categories including:

• Small molecule

• Thiadiazoles

• Recombinant proteins

From investigational drug candidates to competitive intelligence, the Hot Flashes Pipeline Analysis encompasses comprehensive insights – review it today @ Hot Flashes Market Drivers and Barriers, and Future Perspectives

Scope of the Hot Flashes Pipeline Analysis

Coverage: Global

Hot Flashes Pharmaceutical Firms: Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, Pherin Pharmaceuticals, and additional organizations.

Hot Flashes Investigational Treatments: Fezolinetant, NK3R antagonist-AZD4901, Tamoxifen, FP-101, MF101, Gabapentin, RAD1901, and others.

Hot Flashes Therapeutic Evaluation by Product Category: Monotherapy, Combination, Mono/Combination

Hot Flashes Therapeutic Evaluation by Clinical Phases: Discovery, Preclinical, Phase I, Phase II, Phase III

Stay informed in Healthcare Research – uncover future directions for the Hot Flashes Treatment landscape through this comprehensive analysis @ Hot Flashes Emerging Drugs and Major Players

Table of Contents

1. Introduction

2. Executive Summary

3. Hot Flashes: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Hot Flashes – DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Zuclomiphene citrate: Veru Inc

9. Drug profiles in the detailed report…..

10. Mid Stage Products (Phase II)

11. Avexitide: Eiger BioPharmaceuticals

12. Drug profiles in the detailed report…..

13. Mid Stage Products (Phase II)

14. SJX 653: Lundbeck A/S

15. Drug profiles in the detailed report…..

16. Early Stage Products (Phase I)

17. Drug name: Company name

18. Drug profiles in the detailed report…..

19. Preclinical and Discovery Stage Products

20. Drug name: Company name

21. Drug profiles in the detailed report…..

22. Inactive Products

23. Hot Flashes Key Companies

24. Hot Flashes Key Products

25. Hot Flashes - Unmet Needs

26. Hot Flashes - Market Drivers and Barriers

27. Hot Flashes - Future Perspectives and Conclusion

28. Hot Flashes Analyst Views

29. Hot Flashes Key Companies

30. Appendix

About Us

DelveInsight is a premier healthcare-oriented market research and advisory organization that delivers clients superior market intelligence and analysis to facilitate informed business strategies. Supported by a team of seasoned industry specialists and comprehensive knowledge of the life sciences and healthcare industries, we provide tailored research solutions and strategic insights to clients worldwide. Partner with us to obtain superior-quality, precise, and current intelligence to maintain competitive advantage.

Contact Us

Kanishk

kkumar@delveinsight.com